Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: John A. Paul who wrote (2890)	1/30/1998 2:51:00 PM
From: Riverlightning	Respond to of 3906

This should end all the bickering about the patent #. Now lets hope the stock shoots up with this and the other news today. Unlike some of the other posters here, I'm in this one at an average cost of $.84. So a small uptick and its profit territory. I hope it returns to the $6.00 level and more that some of you paid.

To: John A. Paul who wrote (2890)	1/30/1998 2:56:00 PM
From: Krukov	Read Replies (1) \| Respond to of 3906

John & All: This is great news. I can't remember how many times that I have called and asked for that number. The next milestone will be the start of Phase II, but I hope that this news does give us a good lift. Krukov

To: John A. Paul who wrote (2890)	2/1/1998 4:10:00 PM
From: Tunica Albuginea	Read Replies (1) \| Respond to of 3906

John Paul,THE WEAKNESS OF HVSF IS: THEY DON'T HAVE A PATENT ON THE DELIVERY;VIVUS HAS THAT, ( patent # 587 , siliconinvestor.com Let me explain and ask: This is the HVSF Patent claim announcement: biz.yahoo.com It states: -" the U.S. Patent and Trademark Office that it will issue patent no. 5,718,917 entitled ''PGE-1 CONTAINING LYOPHILIZED LIPOSOMES FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION'' to the company." As I read that, THIS IS A PATENT to THE L I Q U I D Liposomal &Alprostadil/PGE Further down the news release states: -"The company's patented process allows the Prostaglandin E-1 to be administered as a liquid via a painless delivery system". My QUESTION is : W H E R E IS THE PATENT to the D E L I V R Y S Y S T E M ??????? The answer is : HVSF does NOT have a patent ; VIVUS has the patent. Here it is: ( This is ONLY PART of the VIVUS PATENT ): Message 3310565 I have othe concerns about liquid Alprostadil: Message 3314238 Re: in regards to HVSF patent.Several points why I fell comfortable: -I asked Dave Yntema ,( Chief Financial Officer at Vivus ) 7 months Ago about " whether Vivus can defend their patent if somebody found a way to insert a liquid through a catheter into the urethra " . ( interestingly enough, at that time I had no idea who HVSF was or that they were working on such a system !!!)His answer was yes.They had just come through defending a patent infringement in the UK. -A gel is going to present several tecnnical problems: =More volume will be needed to allow for residual adhering to plastic. =More vol will mean: more expense; it will be difficult to dose, if patient does not express out all of it. =the gel will be distributed more widely along the length of the urethra.That means that some of it may go all the way back at the base where it could theoretically go all the way back into the bladder. =in fact if the massage is done inappropriately, the gel could be massaged right out of the urethra into the bladder or come out the front.That means that the patient would have to squeeze tight his urethral meatus(the opening of the urethra in the penis) to prevent the gel from coming out during the massage;sort of awkward to squeeze with one hand and massage with the other. -Most importantly, the greater distribution will cause a greater degree of absorption of the material thus greatly enhancing the potential for systemic absorption and thus hypotension and systemic side effects. -preservtion of a liquid in plastic creates problems of absorption & degradation of the material by the plastic. A very significant aspect that people have significantly missed here however is the Irwin-Urology-torch-bearer-Goldstein: he is the one that said MUSE /Alprostadil doesn't work very well in the urethra and here he is advising HVSF about how to administer Alprostadil though the urethra!!!!! Alprostadil in the urethra does the same thing whether ina pellet or a liquid! One final point:other patent attorneys or interested parties/potential HVSF investors must have looked at this: why is HVSF languishing at 96 cents a share? Maybe somebody DID take Gene's advice and forked over $100 to an attorney for a Vivus/HVSF patent search and thus subsequently decided to dump HVSF shares at 96 cents!! Again, IMHO, HVSF WITHOUT A PATENTED DELIVERY SYSTEM (now owned by Vivus is totally worhtless; $1/share!! THE MARKET HATH SPOKEN!!! TA PS For those of you who would like to have a RETURN on your money consider Buying Vivus! Here is the latest, al in the SI thread!!: Message 3309509 Go Vivus!!